View details of this raise on Seedstage

Redwood City, CA

Developing a non-drug treatment for osteopenia using FDA-cleared wearable technology.

• FDA-Cleared Device: Osteoboost offers the only FDA-cleared non-drug treatment for osteopenia.
• Strong Market Demand: The company has a 14,000-person waitlist and achieved $2 million in sales in five months without advertising.
• Innovative Technology: The device uses NASA-researched whole-body vibration technology to maintain bone density.
• Comprehensive Platform: Osteoboost combines its device with a digital platform offering exercise, nutrition, and community support.
• Competitive Advantage: With six US patents and FDA clearance, Osteoboost has a strong competitive position.

Osteoboost is introducing a groundbreaking FDA-cleared medical device designed to address low bone density, specifically targeting osteopenia, a precursor to osteoporosis. The company has developed a wearable belt that utilizes whole-body vibration technology, originally researched by NASA, to help maintain bone density. This device offers a non-drug treatment option for the estimated 47 million Americans with osteopenia, providing a significant alternative to traditional methods like calcium supplements and exercise, which have proven insufficient.

The company has achieved significant milestones, including a 14,000-person waitlist and $2 million in sales within five months without advertising. Osteoboost’s approach combines the medical device with a comprehensive digital platform that includes exercise, nutrition guidance, and community support. This integrated solution not only aims to preserve bone density but also to prevent falls, a common cause of fractures. With six US patents and FDA clearance, Osteoboost has established a strong competitive position. The company is now seeking to expand its market presence and further develop its platform to include additional features and international markets.

Company Info

Osteoboost provides an FDA-cleared, non-drug treatment for osteopenia using a wearable device that delivers targeted vibration therapy.

Osteoboost offers an FDA-cleared, non-drug treatment for osteopenia, a condition affecting 47 million Americans. The company’s innovative device uses whole-body vibration technology, originally developed for astronauts, to maintain bone density. This wearable belt targets the hips and spine, providing a convenient 30-minute daily treatment. Osteoboost’s clinical trials have demonstrated significant reductions in bone density loss, with high patient compliance and no serious adverse events.

Beyond the device, Osteoboost has developed a comprehensive bone health platform that includes exercise, fall prevention, nutrition guidance, and community support. The platform generates valuable longitudinal data, enabling personalized treatment protocols and insights into bone health. With six US patents and FDA clearance, Osteoboost has established a strong competitive position in the market. The company aims to expand its offerings to include osteoporosis treatment and international markets, addressing a growing global demand for effective bone health solutions.